©2024 Stanford Medicine
Gastrointestinal STRING Test With Oral Immunotherapy
Recruiting
Trial ID: NCT04943744
Purpose
This STRING study will examine markers of esophageal inflammation using a minimally-invasive
testing device, the esophageal string test (EST). The primary objective is to determine the
effect of omalizumab (Xolair) and dupilumab (Dupixent) on markers of eosinophilic
inflammation in the esophagus of subjects treated with omalizumab-facilitated
mOIT(mult-allergen oral immunotherapy) and/or mOIT with concurrent dupilumab.
Official Title
Monitoring Gastrointestinal Responses In Food Oral Immunotherapy Using the Esophageal STRING Test
Stanford Investigator(s)
R. Sharon Chinthrajah
Associate Professor of Medicine (Sean Parker Center for Allergy and Asthma Research - Clinic) and of Pediatrics
Eligibility
Inclusion Criteria: • Participants, aged 5-55 years enrolled in the parent COMBINE trial
- Able to swallow the EST.
Exclusion Criteria: • Allergy to, or inability to ingest, gelatin
-
Intervention(s):
device: Entero-tracker
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305